Neurocrine Biosciences Q2 adjusted EPS beats expectations, revenue rises on product portfolio growth

Neurocrine Biosciences

30/07/2026 21:12

Overview
U.S. biopharma firm's Q2 revenue rose 39% yr/yr, driven by product portfolio growth
Adjusted EPS and adjusted net income for Q2 beat analyst expectations
Company completed $2.9 bln Soleno Therapeutics acquisition and raised INGREZZA sales guidance

Outlook
Neurocrine Biosciences raises 2026 INGREZZA net sales guidance to $2.825-$2.875 bln
Company expects 2026 GAAP R&D expense of $1.275-$1.325 bln
Company expects 2026 GAAP SG&A expense of $1.575-$1.6 bln

Result Drivers
INGREZZA GROWTH - INGREZZA Q2 sales rose 15% yr/yr, driven by double-digit prescription volume growth and record new prescriptions, reflecting strong patient demand
CRENESSITY DEMAND - CRENESSITY Q2 sales increased, supported by strong patient demand and approximately 80% reimbursement for dispensed prescriptions
VYKAT XR ADDITION - VYKAT XR contributed $54 mln in Q2 sales from May 18, following the Soleno acquisition, expanding the company's portfolio

Company press release: ID:nPn7l9XCPa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$954.30 mln
 
Q2 Adjusted EPS
Beat
$2.85
$1.34 (18 Analysts)
Q2 EPS
 
$1.39
 
Q2 Adjusted Net Income
Beat
$297 mln
$141.43 mln (18 Analysts)
Q2 Net Income
 
$144 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Neurocrine Biosciences, Inc is $200.00, about 10.6% above its July 29 closing price of $180.79
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
July 30 - Alnylam Q2 revenue rises 67% on increased demand for AMVUTTRA
July 30 - Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
July 30 - Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)